US Patent 11266643 Triaryl compounds for treatment of PD-L1 diseases
Patent 11266643 was granted and assigned to ChemoCentryx on March, 2022 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11266643 Triaryl compounds for treatment of PD-L1 diseases
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.